Background The BRAFV600E mutation can be detected peripherally in the serum of patients with thyroid cancer. The purpose of this study was to establish the value of detecting the peripheral BRAFV600E mutation as a serum tumor marker in this population. Methods In this study, we obtained 94 serum samples from patients with papillary thyroid cancer positive for the BRAFV600E mutation in the tumor itself. The serum samples were analyzed for BRAFV600E mutation using real-time polymerase chain reaction (PCR). Results Sixty-seven patients (71.3%) had papillary thyroid microcarcinoma and 26 patients (27.7%) had underlying lymphocytic thyroiditis. Forty-three patients (45.7%) were found to have stage III or stage IV thyroid cancer. None of the patients had a detectable serum BRAFV600E mutation. Conclusion We were unable to identify peripheral BRAFV600E mutations in patients with papillary thyroid cancer using real-time PCR. Further studies will be needed to validate our results using various diagnostic methods.
All Science Journal Classification (ASJC) codes